KR101560721B1 - the metabolomics portable analysis apparatus and the metabolomics analysis system using the same, the metabolomics analysis method using the same - Google Patents
the metabolomics portable analysis apparatus and the metabolomics analysis system using the same, the metabolomics analysis method using the same Download PDFInfo
- Publication number
- KR101560721B1 KR101560721B1 KR1020140052322A KR20140052322A KR101560721B1 KR 101560721 B1 KR101560721 B1 KR 101560721B1 KR 1020140052322 A KR1020140052322 A KR 1020140052322A KR 20140052322 A KR20140052322 A KR 20140052322A KR 101560721 B1 KR101560721 B1 KR 101560721B1
- Authority
- KR
- South Korea
- Prior art keywords
- data
- spectrum
- server
- spectral data
- mobile terminal
- Prior art date
Links
- 238000004458 analytical method Methods 0.000 title claims abstract description 36
- 238000002705 metabolomic analysis Methods 0.000 title description 8
- 230000001431 metabolomic effect Effects 0.000 title description 7
- 230000002503 metabolic effect Effects 0.000 claims abstract description 47
- 230000003595 spectral effect Effects 0.000 claims abstract description 46
- 238000001228 spectrum Methods 0.000 claims abstract description 42
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 230000028327 secretion Effects 0.000 claims abstract description 18
- 238000012545 processing Methods 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000004060 metabolic process Effects 0.000 claims abstract description 9
- 238000013139 quantization Methods 0.000 claims abstract description 4
- 238000010183 spectrum analysis Methods 0.000 claims abstract description 4
- 230000004044 response Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 12
- 230000009257 reactivity Effects 0.000 abstract description 3
- 229960004316 cisplatin Drugs 0.000 description 21
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 21
- 210000002700 urine Anatomy 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/42—Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
The present invention relates to a spectroscope (200) attached to a mobile terminal (100) for analyzing a spectrum of a body secretion to predict reactivity and disease to a drug. A reading unit inside the mobile terminal 100 for acquiring spectral data of body secretion through the spectroscope 200; An operation unit in the mobile terminal 100 for statistical processing for establishing a prediction model by converting the spectral data into numerical values; And transmits the spectral data to the external server 300. The transmitter 300 compares the transmitted spectral data with the comparison data stored in the server 300, part; And a display unit for displaying the predictive model established based on the spectral data and the prediction result using the predictive model together with the display unit of the mobile terminal.
The server 300 also includes a server 300 for storing the spectrum data and storing the spectrum according to the disease so that the spectrum data can be compared with the spectrum data. The server 300 updates the comparison data in real time The present invention provides a metabolic analysis system using a portable analytical apparatus.
In order to predict a disease by analyzing the spectrum of human body secretion using the metabolic analysis system using the metabolic network analyzer, (1) an application including a spectrum analysis tool is downloaded from the server 300 An application executing step of installing and executing in the mobile terminal 100; (2) a data acquiring step of acquiring spectral data of the body secretion by operating the spectroscope 200; (3) a data quantization step for establishing a prediction model through statistical processing using the spectral data; (4) a data processing step of quantizing the spectrum data through the application; (5) comparing the digitized spectrum data with the comparison data stored in advance in the application or the comparison data stored in advance in the server 300 through the application; And (6) visualizing the spectral data and comparison data most similar to the spectral data, together with a predicted disease type, on the display unit; And a method for analyzing metabolism using the metabolic analysis system.
Description
The present invention relates to a method for analyzing metabolism by attaching a spectroscope to a mobile terminal or smart phone without using expensive specialized equipment such as nuclear magnetic resonance (NMR) or mass spectrometer (MS) The present invention also relates to a metabolic analysis system using the same, and a metabolic analysis method using the same.
Metabolomics is a study to analyze the metabolic materials and metabolic circuits in cells by using high-dimensional statistical methods. It is applied to the clinical field to predict the presence or absence of diseases, drug reactivity or drug toxicity. Application and utilization.
Especially, metabolomics is a study to analyze and study the change of metabolites, which is the final product that comes out through metabolic circuits. Since it can observe metabolic circuits that change due to stimuli such as drugs or diseases, It has many advantages.
Drug-induced toxicity studies have traditionally used cytologic, pathologic, anatomical, and physicochemical methods, and have used these methods collectively to make a final assessment of drug toxicity. In particular, the importance of retrospective discovery toxicology, which is carried out at the national level when toxic issues have emerged, is increasingly emphasized in clinical trials. Since the evaluation of drug toxicity should be continuously carried out from the stage of drug development to the postmarketing period, the detailed criteria are notified as "toxicological test standards for medicines etc." by the Korea Food & Drug Administration. have.
A typical anticancer drug, cisplatin, is a chemical compound in which two chlorine and ammonia are coordinated to a platinum atom. This anticancer drug has been reported to be effective for many types of cancer, including testicular tumors and ovaries, bladder, head and neck, but toxic issues such as serious damage to the kidney are also well known. Therefore, although sufficient water is supplied to the body to minimize the kidney damage caused by the drug, severe side effects such as severe nausea and vomiting, emergency normal bleeding, blood or hematuria, and extreme fatigue may be accompanied at any time. In order to determine the toxicity by cisplatin, levels of creatinine and blood urea nitrogen (BUN) and kidney biopsy have been traditionally used. .
As the number of clinical applications of metabolomics increases, remarkable research results have been reported. The subjects of this research are the field of diagnosis for determining the presence or absence of disease, the field of seeing the response to drugs, And the prediction of prognosis by surgery and surgery.
Existing metabolic research methods have three stages: (1) data acquisition (2) data processing (3) analysis and visualization.
In particular, in the data acquisition phase, expensive equipment such as nuclear magnetic resonance (NMR) or mass spectrometer (MS) is used. Do. The present invention proposes a more convenient and quick metabase management platform by applying an existing platform, which is possible with expensive equipments and professional manpower.
In recent years, there have been attempts to acquire and analyze data using mobile phones. However, all of these attempts have been made to acquire data only or to process simple data. That is, there is no comprehensive analysis method using a complete mobile phone, since only some functions of the mobile phone are used and a conventional computer is required again to obtain the final analysis result.
SUMMARY OF THE INVENTION The present invention has been made in order to solve the above-mentioned problems of the related art.
The object of the present invention is to provide a method for analyzing metabolism by attaching a spectroscope to a mobile terminal or smart phone without using expensive specialized equipment such as nuclear magnetic resonance (NMR) or mass spectrometer (MS) And the like, and to provide a metabolic analysis system using the same, and a metabolic analysis method using the same.
In order to solve the above-mentioned technical problems, the present invention provides a spectroscope (200) attached to a mobile terminal (100) for analyzing spectrum of human body secretion to predict reactivity and disease to a drug. A reading unit inside the
The
In order to predict a disease by analyzing the spectrum of human body secretion using the metabolic analysis system using the metabolic network analyzer, (1) an application including a spectrum analysis tool is downloaded from the
According to the present invention, in the analysis of metabolism, a spectroscope is attached to a mobile terminal, i.e., a smart phone, without using expensive specialized equipment such as nuclear magnetic resonance (NMR) or mass spectrometer (MS) Urine and the like on the screen to inform health states and diseases predicted on the screen, a metabolic analysis system using the analyzer, and a metabolic analysis method using the same.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a conceptual illustration of the metabolic network analyzer of the present invention and the metabolic analysis system using the same.
FIG. 2 illustrates a process of attaching a spectroscope to a smartphone to produce the metabolic medical handheld analyzer of the present invention.
FIG. 3 is a flowchart showing an analysis method of metabolism using the metabolic analysis system. FIG.
FIG. 4 shows blood and histological results of renal toxicity due to cisplatin administration, which was derived from the experimental procedure of the present invention.
Figure 5 shows UV / visible spectrophotometric and metabolic analysis results for toxicity by cisplatin.
Figure 6 shows the smartphone ambassador platform and data collection and statistical analysis.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings.
1. Metabolic path analyzer.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a conceptual illustration of the metabolic network analyzer of the present invention and the metabolic analysis system using the same.
The metabolic laboratory portable analyzing apparatus of the present invention is for analyzing the spectrum of human body secretion to predict the response to a drug and the presence or absence of a disease,
A spectroscope (200) attached to a front of a camera of the mobile terminal (100) to photograph spectral data of body secretion through the camera;
A reading unit inside the
delete
An operation unit in the
A display unit of the mobile terminal (100) for displaying a prediction model established based on the spectrum data together with a prediction result using the prediction model;
And a control unit.
In addition, the
The metabolic medical analyzer according to the present invention can analyze the spectrum of human body secretion to not only diagnose a disease suffered by a user but also inform the current health condition.
The
The reading unit is driven by an application to be described later, and the transmitting and receiving unit and the display unit use hardware and software already installed in the
The human body secretion can utilize all the secreted from the human body, which can recognize the presence or absence of a disease, such as saliva, runny nose and blood, as a target for detection, and urine can be used for the convenience of the user.
The acquisition of the spectral data is performed by photographing the data displayed on the spectroscope attached to the front of the camera built in the mobile terminal (smart phone) with the camera to obtain a spectral picture.
FIG. 2 illustrates a process of attaching a spectroscope to a smartphone to produce the metabolic medical handheld analyzer of the present invention.
2. Metabolic analysis system using portable analytical apparatus.
The metabolic analysis system using the metabolic network portable analyzer of the present invention uses the metabolic network portable analyzer described above,
And a server (300) for storing the spectrum data and for typing and storing spectrum according to the disease so that the spectrum data can be compared with the spectrum data,
And the
3. Metabolic analysis method using metabolic analysis system.
FIG. 3 is a flowchart showing an analysis method of metabolism using the metabolic analysis system. FIG.
The metabolic analysis method using the metabolic analysis system of the present invention is for predicting a disease by analyzing the spectrum of human body secretion by using the metabolomic analysis system using the above-mentioned metabolic system portable analyzer,
(1) an application execution step of downloading an application including a spectrum analysis tool from the
(2) a data acquiring step of acquiring spectral data of the body secretion by operating the
(3) a data quantization step for establishing a prediction model through statistical processing using the spectral data;
4) a data processing step of digitizing the spectrum data through the application;
(5) comparing the digitized spectrum data with the comparison data stored in advance in the application or the comparison data stored in advance in the
(6) visualizing the spectral data and comparison data most similar to the spectral data on the display together with the predicted disease type;
And a control unit.
Apart from the above-described steps, experiments for the implementation of the present invention are as follows.
1) Cisplatin treatment and sample collection in experimental animals
In step 1), cisplatin is injected intraperitoneally into the experimental animal Sprague-Dawley rats at a dose of 10 mg / Kg.
Sprague-Dawley rats to be used as a comparative group are injected intraperitoneally with physiological saline at the same dose.
Urine samples were collected using a metabolic cage for 24 hours before cisplatin injection and 72 to 96 hours after injection to determine the toxicity of the drug.
BUN and Cr levels are measured in comparison and experimental groups to determine whether kidney damage has occurred.
The kidney tissue of Sprague-Dawley rats is collected after 96 hours of cisplatin treatment to confirm kidney damage by histological examination.
Collected urine and tissue samples are kept at -80 ° C until the experiment.
FIG. 4 shows blood and histological results of renal toxicity due to cisplatin administration, which was derived from the experimental procedure of the present invention.
Saline or 10 mg / kg cisplatin were administered to analyze blood and kidney samples obtained from the animals.
Figure 4 (A) shows the difference in blood hematological BUN and Cr levels due to cisplatin. The mean, standard deviation, and associated P-values from student T-tests are displayed.
Fig. 4 (B) shows the results of histological examination due to cisplatin. As a result of H & E staining, the first row shows normal tissue and the second row shows tissue of the cisplatin-treated group.
2) Steps to identify experimental possibilities
Next, in step 2), it is confirmed whether urine samples can be observed by UV spectrophotometer by administration of cisplatin.
400ul of urine sample before / after cisplatin is mixed with 3.6ml of Distilled Water (DW) and diluted to 1/10.
Prepare the analytical sample diluted in a standard 4.5 ml disposable cuvette, and prepare urine specimens before and after administration using a UV spectrophotometer at a wavelength of 400 nm to 720 nm.
The results of the scan are converted into numerical values, and statistical computation is performed using a source code that is implemented in the statistical program MATLAB. Seven samples were designated as training sets to complete the prediction model, and four samples were designated as test sets and applied to the model to predict before and after cisplatin treatment.
Figure 5 shows the results of UV / visible spectrometry and metabolic analyzes of toxicity by cisplatin. The spectra of urine samples before and after the administration of cisplatin were measured, and the measured values were analyzed by PLS-DA method to establish a diagnostic model and predictions.
Figure 5 (A) is a spectrum of the UV / visible spectrometer ranging from 400 to 700 nm for groups before and after cisplatin treatment.
FIG. 5 (B) shows the result of establishing a prediction model by statistically analyzing spectral data using the PLS-DA technique, wherein a black square represents a control sample and a sample circle represents a sample of cisplatin.
Figure 5 (C) is a prediction of the toxicity group for the samples and was performed for four samples excluded from the basic PLS-DA model. The test samples were classified according to the predicted Y-variables of the PLS-DA model.
3) Assembling the Newton spectrometer and attaching it to the camera
In step 3), a paper Newton spectrometer is assembled and attached to a smartphone to create a platform for sample measurement.
First, buy a paper Newton spectrometer kit, assemble it, and block it with black tape to prevent light from passing through each joint. The smartphone case is made to be attached to the camera of the smartphone tightly, and the smartphone and the Newton spectroscope are combined into one. At this time, additional components are assembled and combined so that a 4.5 ml standard cuvette can be placed on the opposite side of the Newton spectrometer which contacts the cellular phone camera.
4) Step of obtaining spectrum from urine sample
The sample prepared in the step 2) is photographed with the camera using the platform prepared in the step 3) to obtain spectral photographs. Spectral photographs are taken from all samples before and after treatment with cisplatin.
5) Processing the spectral data
The spectral photographs obtained in the step 4) are converted into numerical values in the range of 400 nm to 700 nm using a smartphone free application, LearnLight.
The spectral photographs of all urine samples before and after cisplatin treatment are converted to values in the same way.
6) Derivation and visualization of results through data statistics
Finally, the transformed data in step 5) is subjected to multivariate statistical analysis using addi, a free statistical app operated on smartphone, to establish and predict a prediction model. Since the coding source used in step 2) can operate in the same way as the smartphone app addi, multivariate statistical analysis is performed using the same coding source. Likewise, seven samples are designated as training set to make a prediction model, and the remaining four samples are designated as test set. To visualize the final result, visualization is done using addi plot, a plotting app that can be operated on smartphone.
Figure 6 shows the smartphone ambassador platform and data collection and statistical analysis.
Figure 6 (A) is a raw spectral data photograph taken with a camera application of a smartphone. The spectrometer assembly was calibrated so that the prominent spectral lines in the green region coincided with the 550 nm line.
6 (B) shows a graph generated with a LearnLight application on a smartphone.
6 (C) shows a screen image of the PLS-DA statistical analysis and prediction result.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the invention.
It is therefore intended that the appended claims cover such modifications and variations as fall within the true scope of the invention.
100: mobile terminal
200: spectroscope
300: server
Claims (5)
A spectroscope (200) attached to a front of a camera of the mobile terminal (100) to photograph spectral data of body secretion through the camera;
A reading unit inside the mobile terminal 100 for obtaining spectral data from a spectral photograph obtained through the camera;
An operation unit in the mobile terminal 100 for statistical processing for establishing a prediction model by converting the spectral data into numerical values; And
A display unit of the mobile terminal (100) for displaying a prediction model established based on the spectrum data together with a prediction result using the prediction model;
And,
And transmits the spectral data to the external server 300. The transmitter 300 compares the transmitted spectral data with the comparison data stored in the server 300, Wherein the analyzing apparatus further comprises:
And a server (300) for storing the spectrum data and for typing and storing spectrum according to the disease so that the spectrum data can be compared with the spectrum data,
Wherein the server (300) updates the comparison data in real time.
(1) an application execution step of downloading an application including a spectrum analysis tool from the server 300 and installing and executing the application in the mobile terminal 100;
(2) a data acquiring step of acquiring spectral data of the body secretion by operating the spectroscope 200;
(3) a data quantization step for establishing a prediction model through statistical processing using the spectral data;
(4) a data processing step of quantizing the spectrum data through the application;
(5) comparing the digitized spectrum data with the comparison data stored in advance in the application or the comparison data stored in advance in the server 300 through the application; And
(6) visualizing the spectral data and comparison data most similar to the spectral data on the display together with the predicted disease type;
And analyzing the metabolism using the metabolic analysis system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140052322A KR101560721B1 (en) | 2014-04-30 | 2014-04-30 | the metabolomics portable analysis apparatus and the metabolomics analysis system using the same, the metabolomics analysis method using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140052322A KR101560721B1 (en) | 2014-04-30 | 2014-04-30 | the metabolomics portable analysis apparatus and the metabolomics analysis system using the same, the metabolomics analysis method using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101560721B1 true KR101560721B1 (en) | 2015-10-29 |
Family
ID=54430628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140052322A KR101560721B1 (en) | 2014-04-30 | 2014-04-30 | the metabolomics portable analysis apparatus and the metabolomics analysis system using the same, the metabolomics analysis method using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101560721B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200040552A (en) * | 2018-10-10 | 2020-04-20 | 삼성전자주식회사 | Method and apparatus for analyzing spectral information |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008165806A (en) | 2002-07-26 | 2008-07-17 | Olympus Corp | Image processing system |
| US20100309454A1 (en) | 2007-11-30 | 2010-12-09 | Jingyun Zhang | Spectrometers miniaturized for working with cellular phones and other portable electronic devices |
| KR200470398Y1 (en) | 2013-08-13 | 2013-12-13 | 주식회사 지테크인터내셔날 | A strip for urine test |
-
2014
- 2014-04-30 KR KR1020140052322A patent/KR101560721B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008165806A (en) | 2002-07-26 | 2008-07-17 | Olympus Corp | Image processing system |
| US20100309454A1 (en) | 2007-11-30 | 2010-12-09 | Jingyun Zhang | Spectrometers miniaturized for working with cellular phones and other portable electronic devices |
| KR200470398Y1 (en) | 2013-08-13 | 2013-12-13 | 주식회사 지테크인터내셔날 | A strip for urine test |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200040552A (en) * | 2018-10-10 | 2020-04-20 | 삼성전자주식회사 | Method and apparatus for analyzing spectral information |
| US10809127B2 (en) | 2018-10-10 | 2020-10-20 | Samsung Electronics Co., Ltd. | Method and apparatus for analyzing spectral information |
| KR102600150B1 (en) | 2018-10-10 | 2023-11-08 | 삼성전자주식회사 | Method and apparatus for analyzing spectral information |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pantanowitz et al. | An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study | |
| Franck et al. | MALDI imaging mass spectrometry: state of the art technology in clinical proteomics | |
| Patterson et al. | Next generation histology-directed imaging mass spectrometry driven by autofluorescence microscopy | |
| Tortorella et al. | LipostarMSI: comprehensive, vendor-neutral software for visualization, data analysis, and automated molecular identification in mass spectrometry imaging | |
| Murphy et al. | OpenFluor–an online spectral library of auto-fluorescence by organic compounds in the environment | |
| CN104025249B (en) | The use of the windowing analytical data of mass spectrum determined for the holdup time or confirm | |
| de Oliveira Penido et al. | Quantification of cocaine in ternary mixtures using partial least squares regression applied to Raman and Fourier transform infrared spectroscopy | |
| CN106991679A (en) | One kind quantifies recognition methods based on cloud platform urine test paper physical signs | |
| KR101624583B1 (en) | Urine Examination Method and Related Devices | |
| Singh et al. | Translating secondary electrospray ionization–high-resolution mass spectrometry to the clinical environment | |
| CN110222698B (en) | Method and system for water quality analysis based on color information processing | |
| Shahidi-Latham et al. | Evaluation of an accurate mass approach for the simultaneous detection of drug and metabolite distributions via whole-body mass spectrometric imaging | |
| US9990717B2 (en) | Hemoglobin and hematocrit analyzer and analyzing method thereof | |
| Kwon et al. | A smartphone metabolomics platform and its application to the assessment of cisplatin-induced kidney toxicity | |
| Colby et al. | Optimization and validation of high-resolution mass spectrometry data analysis parameters | |
| KR101560721B1 (en) | the metabolomics portable analysis apparatus and the metabolomics analysis system using the same, the metabolomics analysis method using the same | |
| Race et al. | Correlative hyperspectral imaging using a dimensionality-reduction-based image fusion method | |
| Fu et al. | Development of an internal calibration algorithm for ultrahigh-resolution mass spectra of dissolved organic matter | |
| Li et al. | Development of a versatile smartphone-based environmental analyzer (vSEA) and its application in on-site nutrient detection | |
| Isberg et al. | The effect of sample age on the metabolic information extracted from formalin-fixed and paraffin embedded tissue samples using desorption electrospray ionization mass spectrometry imaging | |
| Oesterle et al. | Exposomic biomonitoring of polyphenols by non-targeted analysis and suspect screening | |
| KR102094277B1 (en) | System and method for measuring environmental pollutants or disease tracers using smart device | |
| CN205643169U (en) | Urine detection cloud computing system | |
| CN111289459A (en) | Method, device, equipment and storage medium for detecting component concentration of mixed substance | |
| Taran et al. | The first protocol of stable isotope ratio assessment in tumor tissues based on original research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20181002 Year of fee payment: 4 |